MB07133
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- MB07133
- DrugBank Accession Number
- DB17139
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 440.349
Monoisotopic: 440.10970065 - Chemical Formula
- C17H21N4O8P
- Synonyms
- (2R,4S)-4-amino-1-(5-O-(2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl)-beta-d-arabinofuranosyl)-2(1H)-pyrimidinone
- 2(1h)-pyrimidinone, 4-amino-1-(5-o-((2r,4s)-2-oxido-4-(4-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl)-.beta.-d-arabinofuranosyl)-
- 4-amino-1-(5-o-((2r, 4s)-2-oxido-4-(4-pyridinyl)-1, 3, 2-dioxaphosphorinan-2-yl)-.beta.-d-arabinofuranosyl)-2(1h)-pyrimidinone
- 4-Amino-1-[5-O-[(2R, 4S)-2-oxido-4-(4-pyridinyl)-1, 3, 2-dioxaphosphorinan-2-yl]-b-D-arabinofuranosyl]-2(1H)-pyrimidinone
- External IDs
- MB 07133
- MB-07133
- MB-7133
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- BNL5ERR07R
- CAS number
- 685111-92-6
- InChI Key
- HOAHIHGOMCBTFW-XCJSNOFESA-N
- InChI
- InChI=1S/C17H21N4O8P/c18-13-3-7-21(17(24)20-13)16-15(23)14(22)12(28-16)9-27-30(25)26-8-4-11(29-30)10-1-5-19-6-2-10/h1-3,5-7,11-12,14-16,22-23H,4,8-9H2,(H2,18,20,24)/t11-,12+,14+,15-,16+,30-/m0/s1
- IUPAC Name
- 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-({[(2S,4S)-2-oxo-4-(pyridin-4-yl)-1,3,2lambda5-dioxaphosphinan-2-yl]oxy}methyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one
- SMILES
- NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO[P@]2(=O)OCC[C@H](O2)C2=CC=NC=C2)[C@@H](O)[C@@H]1O
References
- General References
- Not Available
- External Links
- ChemSpider
- 32699216
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Recruiting Treatment Effect of Drugs / Safety Issues / Tolerance 1 1, 2 Completed Treatment Hepatocellular Carcinoma 1 1, 2 Recruiting Treatment Efficacy / MTD / Safety Issues 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 15.7 mg/mL ALOGPS logP -1 ALOGPS logP -1.7 Chemaxon logS -1.4 ALOGPS pKa (Strongest Acidic) 12.56 Chemaxon pKa (Strongest Basic) 5.03 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 166.03 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 99.4 m3·mol-1 Chemaxon Polarizability 39.79 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at November 18, 2022 22:48 / Updated at July 18, 2023 22:58